Rick Harkins is currently a Principal Scientist with Bayer Healthcare’s Global External Innovation and Alliances group located in San Francisco, CA. He is a member of the Science Hub, a partnering arm of Bayer specializing in establishing and managing early stage research collaborations with academic groups and startup biotech companies. Rick has worked in the biopharmaceutical industry for over 30 years and has held positions of increasing responsibility in research and development of protein and gene-based therapeutics. He obtained a BS at Santa Clara University, PhD in Biochemistry at the University of Oregon, and completed postdoctoral studies at Marischal College, Aberdeen University, U.K., and the University of California, San Diego. Rick began his industrial career as a Senior Scientist in the Department of Protein Chemistry at Genentech, and established and led the protein micro-sequencing lab where several human proteins were first purified, cloned and expressed using recombinant DNA technology. Rick’s research in biopharmaceutical drug discovery has contributed to the launch of several marketed biological drugs, including human growth hormone (Protropin), tissue-plasminogen activator (Activase), human interferon beta (Betaseron), and factor VIII (Kogenate).